MAPT and Alzheimer disease: For this purpose,brain homogenate from 5 AD and 5 control samples were combined andtested across a wide range of dilutions (α-syn 1:4 to 1:256,Aβ 1:6.25 to 1:400, tau: 1:2000 to 1:64,000, Figure S4A).